These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 7201059)

  • 1. [Diurnal activity rhythm of HMG-CoA reductase and decrease of lipid levels].
    Mertz DP; Göhmann E; Suermann I; Eisele R; Schatton W
    Med Welt; 1982 Mar; 33(11):405-7. PubMed ID: 7201059
    [No Abstract]   [Full Text] [Related]  

  • 2. The diurnal variation of hepatic HMG-CoA reductase activity is due to changes in the level of immunoreactive protein.
    Ness GC; Chambers CM
    Arch Biochem Biophys; 1996 Mar; 327(1):41-4. PubMed ID: 8615694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of hypocholesterolaemic agents on the expression and activity of 3-hydroxy-3-methylglutaryl-CoA reductase in the fat body of the German cockroach.
    Zapata R; Martín D; Piulachs MD; Bellés X
    Arch Insect Biochem Physiol; 2002 Apr; 49(4):177-86. PubMed ID: 11921076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase.
    Singh DK; Li L; Porter TD
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1020-6. PubMed ID: 16714400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis.
    Kasiske BL; O'Donnell MP; Kim Y; Atluru D; Keane WF
    Kidney Int Suppl; 1994 Feb; 45():S51-3. PubMed ID: 8158898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural mechanism for statin inhibition of HMG-CoA reductase.
    Istvan ES; Deisenhofer J
    Science; 2001 May; 292(5519):1160-4. PubMed ID: 11349148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
    Ugawa T; Kakuta H; Moritani H; Shikama H
    Br J Pharmacol; 2002 Mar; 135(6):1572-8. PubMed ID: 11906972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in sitosterolemia: effects of increased cellular cholesterol and sitosterol concentrations.
    Nguyen LB; Salen G; Shefer S; Tint GS; Ruiz F
    Metabolism; 2001 Oct; 50(10):1224-9. PubMed ID: 11586498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 15-oxa-32-vinyl-lanost-8-ene-3 beta,32 diol on the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase and low density lipoprotein receptor in rat liver.
    Ness GC; Lopez D; Chambers CM; Zhao Z; Beach DL; Ko SS; Trzaskos JM
    Arch Biochem Biophys; 1998 Sep; 357(2):259-64. PubMed ID: 9735166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mode of action of terbufibrol (INN) a hypolipidemic agent on rat liver sterol synthesis.
    Löser R; Schliack M; Moreth W
    Artery; 1982; 10(3):180-92. PubMed ID: 7201785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase activity is inhibited by cholesterol and up-regulated by sitosterol in sitosterolemic fibroblasts.
    Honda A; Salen G; Honda M; Batta AK; Tint GS; Xu G; Chen TS; Tanaka N; Shefer S
    J Lab Clin Med; 2000 Feb; 135(2):174-9. PubMed ID: 10695663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin.
    Duncan RE; El-Sohemy A; Archer MC
    Cancer Lett; 2005 Jun; 224(2):221-8. PubMed ID: 15914273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liver.
    Powell EE; Kroon PA
    J Clin Invest; 1994 May; 93(5):2168-74. PubMed ID: 8182149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sesame as a hypocholesteraemic and antioxidant dietary component.
    Visavadiya NP; Narasimhacharya AV
    Food Chem Toxicol; 2008 Jun; 46(6):1889-95. PubMed ID: 18353516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG-CoA reductase guides migrating primordial germ cells.
    Van Doren M; Broihier HT; Moore LA; Lehmann R
    Nature; 1998 Dec; 396(6710):466-9. PubMed ID: 9853754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticholesterolemic effect of 3,4-di(OH)-phenylpropionic amides in high-cholesterol fed rats.
    Kim SJ; Bok SH; Lee S; Kim HJ; Lee MK; Park YB; Choi MS
    Toxicol Appl Pharmacol; 2005 Oct; 208(1):29-36. PubMed ID: 16164959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A; Rovellini A; Fiorenza AM; Sommariva D
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.